Aclaris Therapeutics

Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through the Therapeutics and Contract Research segments. The Therapeutics segment focuses on identifying, developing, and commercializing different therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Wayne, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Aclaris Therapeutics reports Q1 earnings, highlights ATI-450 trial results

Aclaris Therapeutics reported financial highlights, discussed trial results for ATI-450, and highlighted optimism about its pipeline.
Strengths include targeted PD inhibition in HS study, competitive landscape discussions in atopic dermatitis, and changes in inclusion criteria for studies.
Challenges involve CNS adverse events in HS study, enrollment hurdles in psoriatic arthritis trial, and scrutiny on CK elevations and comparisons to other therapies.
Opportunities lie in potential value creation in immune-inflammatory diseases, market positioning in atopic dermatitis, and patient engagement strategies in RA and PSA studies.

Aclaris Therapeutics progresses ATI-2138 for atopic dermatitis, eyes growth

Aclaris Therapeutics is focused on advancing ATI-2138 for atopic dermatitis with a strong financial position. While facing questions on various fronts, the company's strategic direction and commitment to innovation offer promising opportunities for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

WAYNE, Pa., June 09, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share.  In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters' option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions.

Aclaris Announces Pricing of Public Offering of Common Stock

Aclaris (ACRS) reports encouraging preliminary top-line results from a phase IIa study evaluating its JAK 1/3 inhibitor, ATI-1777, for the treatment of moderate to severe atopic dermatitis.

Aclaris (ACRS) Announces Data on Atopic Dermatitis Candidate

WAYNE, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (Nasdaq: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it intends to offer and sell, subject to market conditions, $75 million in shares of its common stock in an underwritten public offering.  All of the shares of common stock to be sold in the offering will be offered by Aclaris. Aclaris also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions.  The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

Aclaris Announces Proposed Public Offering of Common Stock

CureVac B.V

Hookipa Pharma Inc

Jiuzi Holdings

Ra Medical Systems Inc

The stock prices of RMED, HOOK, JZXN, ACRS, OPRA, and CVAC have fallen noticeably today. These are the details.

RMED, HOOK, JZXN, ACRS, OPRA, CVAC Stock Prices Fall Intraday

Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic dermatitis (AD). The primary efficacy endpoint of this trial was the percent change from baseline in the modified Eczema Area and Severity Index (mEASI) score at week four.

Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure

WAYNE, Pa., May 17, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that Dr. Neal Walker, President and CEO of Aclaris, will present a company overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 1:00 p.m. ET. Management will be available June 1st throughout the day for virtual one-on-one meetings.

Aclaris Therapeutics to Participate in the Jefferies Virtual Healthcare Conference

WAYNE, Pa., May 07, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2021 and provided a corporate update.

Aclaris Therapeutics Reports First Quarter 2021 Financial Results and Provides a Corporate Update

Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

BiotechValley Insights is initiating coverage of ACRS with a "Bullish" rating.

Aclaris Therapeutics: A Potential Big Pharma Deal May Be In The Horizon

WAYNE, Pa., Feb. 10, 2021 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 8:00 a.m. ET. Management will be available February 25th throughout the day for virtual one-on-one meetings.

Aclaris Therapeutics to Participate in the 10th Annual SVB Leerink Global Healthcare Conference

Aclaris (ACRS) posts favorable preliminary topline results from a phase IIa study evaluating its investigational oral candidate ATI-450 for treating moderate to severe rheumatoid arthritis. Shares up.

Aclaris (ACRS) Up on Preliminary Data for MK2 Inhibitor in RA

The stock price of Aclaris Therapeutics Inc (NASDAQ: ACRS) increased by 220.24% today. This is why it happened.

ACRS Stock Price Increases 220.24%: Why It Happened

Investors are excited about the biotech's clinical trial results.

Why Aclaris Therapeutics Stock Skyrocketed More Than 200% Today

Aclaris Therapeutics stock triples after positive data on arthritis treatment

Aclaris Therapeutics (ACRS) stock is soaring higher on Tuesday after revealing results from a recent Phase 2a clinical trial. The post ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today appeared first on InvestorPlace.

ACRS Stock Alert: Why Aclaris Therapeutics Is Up Over 200% Today

Celyad

Gritstone Oncology Inc

Merus

Minerva Neurosciences

Tenax Therapeutics

A slew of biopharma stocks are making big moves Tuesday on the back of clinical trial readouts as well announcements regarding M&A and tie-ups. Merus, Lilly In $1.68B Oncology Deal: Dutch-based Merus NV (NASDAQ: MRUS) announced a R&D collaboration and licensing agreement with large-cap pharma Eli Lilly And Co (NYSE: LLY) for developing up to three CD-engaging T-cell redirecting bispecific antibody therapies for oncology indications.

Why Aclaris, Tenax, Gritstone, Merus, Minerva And Celyad Are Rallying Today

Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares more than doubled to start out the week after the company announced positive results from its midstage rheumatoid arthritis (RA) study.

Is Aclaris Therapeutics a Stock to Buy After Nearly 200% Run-Up and Now This?

Investors need to pay close attention to Aclaris Therapeutics (ACRS) stock based on the movements in the options market lately.

Implied Volatility Surging for Aclaris Therapeutics (ACRS) Stock Options

WAYNE, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the formation of a new Scientific Advisory Board consisting of Stanley Cohen, MD, Marco Colonna, MD, James Krueger, MD, PhD, and Michael Weinblatt, MD.

Aclaris Therapeutics Announces Formation of New Scientific Advisory Board

WAYNE, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that management will participate in a virtual fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on Wednesday, December 2, 2020 at 7:30 a.m. ET. Management will be available December 1st and 2nd throughout the day for virtual one-on-one meetings.

Aclaris Therapeutics to Participate in the Evercore ISI 3rd Annual HealthCONx Conference

Aclaris (ACRS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aclaris (ACRS) Upgraded to Buy: Here's What You Should Know

WAYNE, Pa., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2020 and provided a corporate update.

Aclaris Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Corporate Update

Aclaris Therapeutics (ACRS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aclaris (ACRS) initiates a phase IIa study on ATI-1777, for the treatment of moderate-to-severe atopic dermatitis.

Aclaris (ACRS) Begins Phase II Study on Eczema Candidate

WAYNE, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that the first patient has been dosed in Aclaris' Phase 2a clinical trial of ATI-1777, an investigational topical “soft” Janus kinase (JAK) 1/3 inhibitor, for the treatment of moderate to severe atopic dermatitis (AD). ATI-1777 was developed internally utilizing Aclaris' proprietary KINect™ drug discovery platform.

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-1777, an Investigational Topical “Soft” JAK 1/3 Inhibitor, for the Treatment of Moderate to Severe Atopic Dermatitis

News for Aclaris Therapeutics Stock (ACRS)